Integrated BioPharma Inc (INBP) reported QQ3 2025 results with a modest top-line expansion and meaningful improvement in profitability and cash generation despite a small-scale operation. Revenue totaled $13.95 million, up 6.09% year-over-year and 10.57% quarter-over-quarter, while gross profit reached $1.55 million for a gross margin of 11.12%. EBITDA stood at $1.043 million and operating income at $0.739 million, yielding an operating margin of 5.30% and a net income of $0.611 million (EPS: $0.02). The quarter benefited from favorable cost control and mix shift, helping EBITDA and net income expand meaningfully versus prior periods (YoY EBITDA margin 7.48%; net income margin 4.38%).